Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to 23.11%.

  • Macrogenics' EBITDA Margin fell 277900.0% to 23.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 51.19%, marking a year-over-year increase of 217200.0%. This contributed to the annual value of 44.65% for FY2024, which is 292300.0% down from last year.
  • Macrogenics' EBITDA Margin amounted to 23.11% in Q3 2025, which was down 277900.0% from 163.02% recorded in Q2 2025.
  • In the past 5 years, Macrogenics' EBITDA Margin ranged from a high of 436.88% in Q2 2023 and a low of 1686.45% during Q2 2024
  • Its 5-year average for EBITDA Margin is 245.25%, with a median of 158.98% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -21233400bps in 2024, then surged by 15234400bps in 2025.
  • Over the past 5 years, Macrogenics' EBITDA Margin (Quarter) stood at 410.55% in 2021, then skyrocketed by 104bps to 17.66% in 2022, then tumbled by -2532bps to 429.51% in 2023, then surged by 91bps to 38.58% in 2024, then soared by 160bps to 23.11% in 2025.
  • Its EBITDA Margin was 23.11% in Q3 2025, compared to 163.02% in Q2 2025 and 311.11% in Q1 2025.